EIGR recently announced an expanded licensing deal MRK
MRK is now partnered with EIGR in both their Lonafamib programs. These programs will initiate Ph3 trials before the end of Q1/19.
EIGR is a leader in Hepatitis D, likely to become a disease of greater concern as Central Asian human filth continues to pour into Western Civilization.
EIGR raised cash on 5/18 expanding its runway into 2020.
Also, it would be wise to track the prospect of EIGR receiving a priority review voucher.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.